Literature DB >> 16542321

Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.

R Williams1, L Kopala, A Malla, G Smith, L Love, R Balshaw.   

Abstract

OBJECTIVE: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment.
METHOD: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years.
RESULTS: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized.
CONCLUSION: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542321     DOI: 10.1111/j.1600-0447.2006.00757.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  6 in total

1.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

2.  The Evolution of Long-Acting Antipsychotics Use in Québec between 2003 and 2017.

Authors:  Marc-André Roy
Journal:  Can J Psychiatry       Date:  2020-02-07       Impact factor: 4.356

3.  Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.

Authors:  Stefanie N Rezansoff; A Moniruzzaman; S Fazel; R Procyshyn; J M Somers
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-06-23       Impact factor: 4.328

4.  Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.

Authors:  Haya Ascher-Svanum; William S Montgomery; David P McDonnell; Kristina A Coleman; Peter D Feldman
Journal:  Int J Gen Med       Date:  2012-05-04

Review 5.  Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-10-24

6.  Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Shuhei Kudo; Masamichi Ishioka; Yasushi Sato; Kazutoshi Kubo; Norio Yasui-Furukori
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-09       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.